Quoin Pharmaceuticals, Ltd. (QNRX) Reports Q2 Loss of $3.24/sh

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. REGN
2. CRWD
3. ABBV
4. CL
5. TFII
6. LYB
7. LITE
8. NVT
9. KVUE
10. BP

Go back to Quoin Pharmaceuticals, Ltd. (QNRX) Reports Q2 Loss of $3.24/sh

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

August 18, 2022 7:00 AM EDT

Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a product for the treatment of scleroderma Closes $16.8 million public offering, with net proceeds of approximately $15.0 million

ASHBURN, Va., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today provides a business update and announces financial results for the second quarter of 2022 ended June 30, 2022.

... More